A Randomized, Double-Blind, Multicenter Study of Denosumab ComparedWith Zoledronic Acid (Zometa) in the Treatment of Bone Disease inSubjects with Newly Diagnosed Multiple Myeloma

Phase 1

• Conditions: Multiple Myeloma; Therapeutic area: Diseases [C] - Cancer [C04]; MedDRA version: 14.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2010-020454-34-IT
• Lead Sponsor: AMGEN INC.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-15
• Study Completion: 2019-03-29
• Last Update Posted: 21 December 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 1718

Inclusion Criteria

- Adults with newly diagnosed multiple myeloma; - Radiographic evidence of at least 1 bone lesion; - Plan to receive primary frontline anti-myeloma therapies; - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; - Adequate organ function; - Written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 560
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 960

Exclusion Criteria

- Nonsecretory multiple myeloma (unless baseline serum free light chain level is elevated); - Plasma cell leukemia; - Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome; - Previous treatment with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days]). Anti-myeloma therapy (excluding bisphosphonates) may be started before randomization if the subject has signed informed consent and screening blood samples have been collected for central analysis. - Planned radiation therapy or surgery to bone (does not include procedures; performed before randomization) - Prior administration of denosumab; - Prior or current IV bisphosphonate administration; - Use of oral bisphosphonates within the past 1 year; - Prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified